Abstract:Diabetes is a medical condition associated with impaired glucose regulation caused either due to insufficient insulin production or resistance to insulin (Type 2 diabetes, gestational diabetes) or the absence of insulin through the selective killing of beta cells in the pancreas (Type 1 diabetes). Irregular insulin production leads to various health complications. To prevent such complications, patients must adhere to medical recommendations before availing of any advanced insulin therapy(ies), considered productive for the treatment. Natural insulin, although highly effective in controlling blood glucose levels, patients are often at risk of developing hypoglycemia and many other complications. This has led to the development of insulin analogs, the modified variants of natural insulin having a minimal risk of causing hypoglycemia. Besides the development of analogs, the mode of insulin delivery is also considered critical in achieving better glycemic control in diabetic patients. Until recently, various exogenous insulin delivery methods were practiced, but effective glycemic control without any associated risk and ease of delivery remains a subject of paramount concern. It countered attenuation or delayed onset of diabetes-associated complications without a permanent cure, raising an unmet demand for insulin formulations and delivery methods that offer stability, biocompatibility, reproducibility, precision dosing, non-immunogenicity, and safety. The current practice utilizes non-physiological delivery methods with less invasive administration routes, offering glycemic stability and therapeutic effectiveness. This review focuses on the recent advances made and future perspectives envisioned about newer insulin therapies and delivery methods that tend to improve the management of diabetes by inculcating ideas to reduce the disease's severity and improve the quality of life.

Newer insights into the drug delivery approaches of α-glucosidase inhibitors

Reappraisal and perspectives of clinical drug–drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus

Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes

Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review

Efficacy and Cardiovascular Safety of Alpha Glucosidase Inhibitors

Progress on Glucosidase Inhibitors

Emerging Technologies to Achieve Oral Delivery of GLP-1 and GLP-1 Analogs for Treatment of Type 2 Diabetes Mellitus (T2DM)

Recent Advances in the Development of Alpha-Glucosidase and Alpha-Amylase Inhibitors in Type 2 Diabetes Management: Insights from In silico to In vitro Studies

Peptide GLP-1 receptor agonists: From injection to oral delivery strategies

Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones

Managing Diabetes with Hydrogel Drug Delivery

An apprise on novel drug delivery systems for management of diabetes mellitus

Recent advances in glucose-responsive insulin delivery systems: novel hydrogels and future applications

Investigation of Alogliptin-Loaded In Situ Gel Implants by 23 Factorial Design with Glycemic Assessment in Rats

Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards

A review of oral semaglutide available evidence: A new era of management of diabetes with peptide in a pill form

Recent Advances in the Drugs and Glucose-Responsive Drug Delivery Systems for the Treatment of Diabetes: A Systematic Review

Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges

Exploration of Potent Human α ‐Glucosidase Inhibitors Using In Silico Approaches: Molecular Docking, DFT, Molecular Dynamics Simulations, and MMPBSA

New selective inhibitors of α‐glucosidase for the treatment of type 2 diabetes mellitus

Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update